Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

ede and can develop into cervical cancer. The primary cause of such abnormalities is infection with certain HPV types, of which HPV-16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low grade cervical dysplasia, (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any type of CIN.

About HspE7:

The company's lead candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... International Corporation (NASDAQ: PRXL ) will release financial results ... August 5 th , 2015 after the close of the ... at www.PAREXEL.com and on the PRNewswire website at ... call and live webcast at 10:00 a.m. EDT on Thursday, ... access the webcast, visit PAREXEL,s website at www.PAREXEL.com , ...
(Date:7/7/2015)... , July 7, 2015   InspireMD, ... "Company"), a leader in embolic protection systems ("EPS"), ... Embolic Protection System integrated with MicroNet ™ ... Coronary Stent New Product Innovation Award.  Through active ... of analysts and consultants recognize the successful introduction ...
(Date:7/7/2015)... Minn. , July 7, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... of its previously announced public offering of 32,000,000 units. Each ... one Series A warrant to purchase one share of ... unit. Investors whose purchase of units in the offering ...
Breaking Medicine Technology:PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... June 08, 2007 /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today ... research project with scientists at Fox,Chase Cancer Center ... Lexicon researchers have discovered a novel and,surprising role ... T lymphocytes. These findings have been published in,the ...
... - NuPathe Inc., a,privately held specialty pharmaceutical ... Phase I study of NP101,SmartRelief, a novel ... NP101 combines NuPathe's SmartRelief(TM) proprietary,iontophoretic transdermal technology ... acute migraine in the United,States. Sumatriptan is ...
Cached Medicine Technology:Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 2Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 3NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
(Date:7/7/2015)... ... July 07, 2015 , ... Researchers at UC ... what worked (or didn’t) and how similar programs can be improved. , Interviewing ... Living TeleHealth Community of Practice (HEALTH COP) program, the team identified four factors ...
(Date:7/7/2015)... ... July 07, 2015 , ... WiseWear®, a ... launched their first line of luxury smart jewelry called the Socialite™ collection. The ... ship this fall. , “The Socialite collection was crafted to inspire women ...
(Date:7/7/2015)... ... 2015 , ... Dermatologists from the Mount Sinai Health System ... possible melanomas and 46 potential non-melanoma skin cancers (basal cell and squamous cell ... Ideas Festival, which was held from June 25 through July 4, 2015, in ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... announced today that the two firms have merged to form Camber Collective. ... and biopharma sectors. The merger combines SwitchPoint’s strategy consulting expertise with Hope ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... group whose board is limited to permit holders. The Medical Cannabis Alliance of ... move the industry forward and are committed to making sure patients have access ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 2Health News:UC Davis Study Identifies Tools, Strategies for Enhancing Obesity Prevention in Rural Communities 3Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 3Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 4Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2
... 11 The Chasen Group ... ergonomic interventions to prevent workplace injuries, increase employee ... Wiley and Sons, the foremost publisher of scientific ... "Safety Manager,s Guide to Office Ergonomics," written by ...
... an invited panelist in the second annual SOA in Healthcare conference to ... ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, Dave Shaver, will ... to be held on June 2 - 4 in Chicago, Illinois. ...
... new alternative for patientsRESEARCH TRIANGLE PARK, N.C., May 11 ... that the U.S. Food and Drug Administration (FDA) has ... ODT uses a novel drug-delivery formulation to provide ... pleasant taste and disintegrates on the tongue. One ...
... RAPIDS, Mich., May 11 Lambert, Edwards ... Inc. to its growing roster of health care clients.Aspirus ... Wis. providing health care services to residents in north-central ... Aspirus Wausau Hospital is consistently recognized as one of ...
... ProCitius Research jointly announce a strategic alliance created to provide clients ... ... Toronto, Canada and Chennai, India (PRWEB) - Dalton Pharma Services and ... with contract chemistry services of exceptional value. , ...
... During National Women,s Health Week Points to Importance of ... today on gender-based differences in mental health shows women ... from major depression. The report addresses many other ... and violence can have on long term mental health, ...
Cached Medicine News:Health News:Office Ergonomics Book Reveals Early-Stage Solutions 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: